HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: Implications for disease control by physiological immune surveillance

Leukemia

Volumn 25, Issue 6, 2011, Pages 1036-1039

  Shah, N ^a   Decker, W K ^a   Lapushin, R ^a   Xing, D ^a   Robinson, S N ^a   Yang, H ^a   Parmar, S ^a   Tung, S S ^a   O'Brien, S ^a   Fernandez Via M ^a   Shpall, E J ^a   Wierda, W G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; HLA A1 ANTIGEN; HLA B8 ANTIGEN; HLA C ANTIGEN; HLA C7 ANTIGEN; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ALLOTRANSPLANTATION; ANTIGEN PRESENTATION; ARTICLE; CANCER GROWTH; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE CONTROL; FEMALE; GENE FREQUENCY; GENE LOCUS; HAPLOTYPE; HLA SYSTEM; HOMOZYGOSITY; HUMAN; IMMUNOSURVEILLANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; FEMALE; HAPLOTYPES; HOMOZYGOTE; HUMANS; IMMUNOLOGIC SURVEILLANCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 79958092540     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.30     Document Type: Article

References (11)

1. Vajdic CM, van Leeuwen MT. What types of cancers are associated with immune suppression in HIV? Lessons from solid organ transplant recipients. Curr Opin HIV AIDS 2009; 4: 35-41.
2. Law GR. Invited commentary: do clusters of leukemia and lymphoma provide evidence for an infectious cause? Am J Epidemiol 2005; 162: 823-824.
3. Ben-Bassat I, Raanani P, Gale RP. Graft-versus-leukemia in chronic lymphocytic leukemia. BoneMarrow Transplant 2007; 39: 441-446. (Pubitemid 46605201)
4. Ritgen M, Bottcher S, Stilgenbauer S, Bunjes D, Schubert J, Cohen S et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia 2008; 22: 1377-1386. (Pubitemid 352006082)
5. Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, Chessia M et al. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 2002; 100: 2123-2131. (Pubitemid 35001247)
6. Khouri IF, Saliba RM, Admirand J, O'Brien S, Lee MS, Korbling M et al. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 2007; 137: 355-363. (Pubitemid 46650260)
7. Penn DJ, Damjanovich K, Potts WK. MHC heterozygosity confers a selective advantage against multiple-strain infections. Proc Natl Acad Sci USA 2002; 99: 11260-11264. (Pubitemid 34920913)
8. Thursz MR, Thomas HC, Greenwood BM, Hill AV. Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet 1997; 17: 11-12.
9. Doherty PC, Zinkernagel RM. Enhanced immunological surveillance in mice heterozygous at the H-2 gene complex. Nature 1975; 256: 50-52.
10. Therodorou I, Abel L, Mauro F, Duprey B, Magnac C, Payelle- Brogard B et al. High occurrence of DRB1 11 in chronic lymphocytic leukaemia families. Br J Haematol 2002; 119: 713-715. (Pubitemid 35366213)
11. Hojjat-Farsangi M, Jeddi-Tehrani M, Amirzargar A, Razavi SM, Sharifian RA, Rabbani H et al. Human leukocyte antigen class II allele association to disease progression in Iranian patients with chronic lymphocytic leukemia. Hum Immunol 2008; 69: 666-674.